摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-nitro-1H-pyrazole-3-carboxylic acid 4-hydroxy-cyclohexylamide | 844443-75-0

中文名称
——
中文别名
——
英文名称
4-nitro-1H-pyrazole-3-carboxylic acid 4-hydroxy-cyclohexylamide
英文别名
——
4-nitro-1H-pyrazole-3-carboxylic acid 4-hydroxy-cyclohexylamide化学式
CAS
844443-75-0
化学式
C10H14N4O4
mdl
——
分子量
254.246
InChiKey
FECNFKZDMSABII-LJGSYFOKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    577.3±50.0 °C(Predicted)
  • 密度:
    1.46±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.35
  • 重原子数:
    18.0
  • 可旋转键数:
    3.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    121.15
  • 氢给体数:
    3.0
  • 氢受体数:
    5.0

反应信息

点击查看最新优质反应信息

文献信息

  • Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
    申请人:Curry Jayne Elizabeth
    公开号:US20080161355A1
    公开(公告)日:2008-07-03
    The invention provides a combination of a compound having the formula (0) and two or more further anti-cancer agents: or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR 9 (C═O) or 0(C═O) wherein R 9 is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
    本发明提供了一种由具有公式(0)的化合物和两种或更多进一步的抗癌剂组成的组合物:或其盐或互变异构体或N-氧化物或溶剂化物;其中X是一个R1-A-NR4-或一个5-或6-成员的碳环或杂环环;A是一个键,SO2,C═O,NR9(C═O)或0(C═O),其中R9是氢或C1-4烃基,可以选择地被羟基或C1-4烷氧基取代;Y是一个键或长度为1、2或3个碳原子的烷基链;R1是氢;具有3到12个环成员的碳环或杂环基团;或者是一个C1-8烃基,可以选择地被一个或多个取代基所取代,所述取代基选自卤素(例如)、羟基、C1-4烃氧基、基、单-或双C1-4烃基基和具有从3到12个环成员的碳环或杂环基团,其中烃基的1或2个碳原子可以选择性地被O、S、NH、SO、SO2中的一个原子或基取代;R2是氢;卤素;C1-4烷氧基(例如甲氧基);或一个C1-4烃基,可以选择地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)所取代;R3选自氢和具有从3到12个环成员的碳环和杂环基团;R4是氢或一个C1-4烃基,可以选择地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)所取代。
  • Pharmaceutical Compounds
    申请人:Curry Jayne Elizabeth
    公开号:US20080161251A1
    公开(公告)日:2008-07-03
    The invention provides a combination of a cytotoxic compound or signalling inhibitor and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 - or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR g (C═O) or 0(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
    本发明提供了一种细胞毒性化合物或信号抑制剂与式(0)的化合物或其盐、互变异构体、N-氧化物或溶剂化物的组合物;其中X是一个R1-A-NR4-或5-或6-成员的碳环或杂环;A是一个键,SO2,C═O,NRg(C═O)或0(C═O),其中Rg是氢或C1-4羟基或C1-4烷氧基取代的烷基;Y是一个键或1、2或3个碳原子长的烷基链;R1是氢;一个从3到12个环成员的碳环或杂环基团;或一个C1-8烷基基团,可选地取代一个或多个取代基,所述取代基选自卤素(例如)、羟基、C1-4烷氧基、基、C1-4单取代或双取代烷基基和从3到12个环成员的碳环或杂环基团,其中烷基基团的1或2个碳原子可以选为O、S、NH、SO或SO2中的原子或基团;R2是氢;卤素;C1-4烷氧基(例如甲氧基);或一个C1-4烷基基团,可选地取代卤素(例如)、羟基或C1-4烷氧基(例如甲氧基);R3选自氢和从3到12个环成员的碳环或杂环基团;R4是氢或一个C1-4烷基基团,可选地取代卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)。
  • 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS
    申请人:Berdini Valerio
    公开号:US20080200509A1
    公开(公告)日:2008-08-21
    The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
    该发明提供了公式(0)的化合物,或其盐,互变异构体,N-氧化物或溶剂化物,用于预防或治疗由细胞周期依赖性激酶和糖原合成酶激酶3介导的癌症等疾病状态和病情。 在公式(0)中: X是R1-A-NR4-基团或5或6成员的碳环或杂环环; A是键,SO2,C═O,NRg(C═O)或O(C═O),其中Rg是氢或C1-4烃基,可选地被羟基或C1-4烷氧基取代; Y是键或1、2或3个碳原子的烷基链; R1是氢;具有3到12个环成员的碳环或杂环基团;或C1-8烃基,可选地被一个或多个取代基所取代,所述取代基选自卤素(例如)、羟基、C1-4烃氧基、基、单或双C1-4烃基基,以及具有3到12个环成员的碳环或杂环基团,其中烃基的1或2个碳原子可以选择性地被O、S、NH、SO、SO2中的一个原子或基团所取代; R2是氢;卤素;C1-4烷氧基(例如甲氧基);或C1-4烃基,可选地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)所取代; R3选自氢和具有3到12个环成员的碳环或杂环基团; R4是氢或C1-4烃基,可选地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)所取代。
  • Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S
    申请人:Wyatt Paul Graham
    公开号:US20080306069A1
    公开(公告)日:2008-12-11
    The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group RO; (e) a group R a; (f) a group RIb; (g) a group RIc; (h) a group RId; and 0) 2,6-difluorophenylamino; wherein R) 0υ, r R>llaa, T Rj HbD, T R) HcC, r R>Iidα, r R>>2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdk1 or cdk2) and glycogen synthase kinase-3 activity.
    该发明提供了式(I)的化合物,或其盐、互变异构体、N-氧化物或溶剂化物,其中:R1选择自:(a)2,6-二氯苯基;(b)2,6-二氟苯基;(c)2,3,6-三取代苯基,其中苯基的取代基选择自、甲基和甲氧基;(d)羟基取代基;(e)R a基;(f)RIb基;(g)RIc基;(h)RId基;和(i)2,6-二氟苯基基;其中R) 0υ,r R>llaa,T Rj HbD,T R) HcC,r R>Iidα,r R>>2zaa,r R>22bD和RJ如权利要求所定义。该化合物具有作为cdk激酶(如cdk1或cdk2)和糖原合成酶激酶-3活性抑制剂的活性。
  • Combinations of Pyrazole Kinase Inhibitors
    申请人:CURRY Jayne Elizabeth
    公开号:US20110002879A1
    公开(公告)日:2011-01-06
    The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 —; A is a bond, C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
    该发明提供了一种组合物,包括细胞毒性化合物、信号抑制剂、辅助剂或两种或更多进一步的抗癌剂,以及具有以下式子(Ib)的化合物或其盐、互变异构体或溶剂化物: 其中, X是一个基团R1-A-NR4—; A是一个键,C═O,NRg(C═O)或O(C═O),其中Rg是氢或C1-4烃基,可选择性地被羟基或C1-4烷氧基取代; Y是一个键或长度为1、2或3个碳原子的烷基链; R1是一个具有3到12个环成员的碳环化或杂环化基团;或一个C1-8烃基,可选择性地被、羟基、C1-4烷氧基、基、单-或双-C1-4烷基基和具有3到12个环成员的碳环化或杂环化基团中的一个或多个取代基取代,并且烃基的1或2个碳原子可选择性地被O、S、NH、SO或SO2中的一个或多个原子或基团取代; R2是氢、卤素、C1-4烷氧基(例如甲氧基)或一个C1-4烃基,可选择性地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)取代; R3选择自具有3到12个环成员的碳环化和杂环化基团; R4是氢或一个C1-4烃基,可选择性地被卤素(例如)、羟基或C1-4烷氧基(例如甲氧基)取代。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸